Long-term safety and efficacy of rilpivirine plus nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 7-year roll-over study from phase 2 and 3 clinical studies

被引：0
|
作者：
Molina, J-M [1 ]
Faetkenheuer, G. [2 ]
Van Wijngaerden, E. [3 ]
Cahn, P. [4 ]
Ene, L. [5 ]
Lombaard, J. [6 ]
Zakharova, N. [7 ]
Van Eygen, V. [8 ]
Vanveggel, S. [8 ]
Van Solingen-Ristea, R. [8 ]
机构：
[1] Univ Paris Diderot, Dept Infect Dis, Paris, France
[2] Univ Cologne, Dept Internal Med, Cologne, Germany
[3] Univ Hosp Leuven, Dept Gen Internal Med, Leuven, Belgium
[4] Fdn Huesped, Buenos Aires, DF, Argentina
[5] Spitalul Boli Infect & Trop Dr Victor Babes Bucur, Bucharest, Romania
[6] Josha Res, Bloemfontein, South Africa
[7] Ctr Prophylaxis & Control AIDS & Infect Dis, St Petersburg, Russia
[8] Janssen Res & Dev, Beerse, Belgium
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE3/18
引用
收藏
页码：96 / 96
页数：1
相关论文
共 29 条
  • [21] Safety of tildrakizumab in patients with preexisting metabolic syndrome: Long-term data from the post hoc analysis of two phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)
    Lebwohl, Mark G.
    Mehta, Nehal N.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, M. Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB51 - AB51
  • [22] Long-Term Safety and Efficacy of Risankizumab Treatment in Patients With Crohn's Disease: 3-Year Interim Results From the Ongoing Phase 2 Open-Label Extension Study
    Ferrante, Marc
    Feagan, Brian G.
    Panes, Julian
    Baert, Filip
    Louis, Edouard
    Dewit, Olivier
    Kaser, Arthur
    Duan, Weijiang
    Gustafson, Dawn
    Liao, Xiaomei
    Wallace, Kori
    Kalabic, Jasmina
    D'Haens, Geert R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S466 - S466
  • [23] Long-term safety and efficacy of benralizumab in patients with severe, un-controlled asthma: 1-year results from the BORA phase 3 extension trial (vol 7, pg 46, 2019)
    Busse, W. W.
    Bleecker, E. R.
    FitzGerald, J. M.
    LANCET RESPIRATORY MEDICINE, 2019, 7 (01): : E1 - E1
  • [24] Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)
    Lebwohl, Mark G.
    Leonardi, Craig L.
    Mehta, Nehal N.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, M. Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (02) : 398 - 407
  • [25] A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension
    Kahn, Rene S.
    Silverman, Bernard L.
    DiPetrillo, Lauren
    Graham, Christine
    Jiang, Ying
    Yin, Jiani
    Simmons, Adam
    Bhupathi, Vasudev
    Yu, Bei
    Yagoda, Sergey
    Hopkinson, Craig
    McDonnell, David
    SCHIZOPHRENIA RESEARCH, 2021, 232 : 45 - 53
  • [26] Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
    Ye, Jing Christine
    Schinke, Carolina
    Touzeau, Cyrille
    Minnema, Monique
    van de Donk, Niels
    Rodriguez-Otero, Paula
    Mateos Manteca, Maria-Victoria
    Rasche, Leo
    Vishwamitra, Deeksha
    Singh, Indrajeet
    Qin, Xiang
    Campagna, Michela
    Hilder, Brandi
    Tolbert, Jaszianne
    Renaud, Thomas
    Heuck, Christoph
    Kane, Colleen
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S99 - S99
  • [27] Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    Rasche, Leo
    Schinke, Carolina
    Touzeau, Cyrille
    Minnema, Monique C.
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Ye, Jing Christine
    Vishwamitra, Deeksha
    Singh, Indrajeet
    Qin, Xiang
    Campagna, Michela
    Masterson, Tara
    Hilder, Brandi W.
    Tolbert, Jaszianne
    Renaud, Thomas
    Heuck, Christoph
    Kane, Colleen
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S561 - S562
  • [28] TWO PHASE 3, LONG-TERM STUDIES OF ESKETAMINE NASAL SPRAY PLUS ORAL ANTIDEPRESSANT IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION: SUSTAIN-1 (RANDOMIZED, WITHDRAWAL, DOUBLE-BLIND, RELAPSE PREVENTION STUDY) AND SUSTAIN-2 (OPEN-LABEL, SAFETY AND EFFICACY STUDY)
    Singh, J.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 105 - 106
  • [29] Safety and tolerability of tildrakizumab, an anti-interleukin-23p19 monoclonal antibody, in patients with chronic plaque psoriasis over two years of treatment: Results from long-term extensions of two phase III clinical studies (reSURFACE 1 and reSURFACE 2)
    Reich, Kristian
    Papp, Kim
    Thaci, Diamant
    Kimball, Alexa B.
    Sinclair, Rodney
    Tyring, Stephen K.
    Cichanowitz, Nicole
    Li, Qing
    la Rosa, Carmen
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB251 - AB251
123